Precision Biosciences Activates Second Clinical Site At Washington University School Of Medicine As It Begins The FUNCTION-DMD Clinical Tria
Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St. Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy with initial safety data targeted for year-end 2026. In its updated corporate deck and as previously reported, the Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts. The Company is targeting year-end 2026 for the next program update.
Also in its updated corporate deck, the Company announced activation of a second clinical site at Washington University School of Medicine in St.
Louis, Missouri as it commences the FUNCTION-DMD clinical trial evaluating PBGENE-DMD for Duchenne muscular dystrophy with initial safety data targeted for year-end 2026.
In its updated corporate deck and as previously reported, the Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log (10-fold) reduction in cccDNA-derived transcripts.
The Company is targeting year-end 2026 for the next program update.